2012-02-08 13:32:06 -

MENLO PARK, Calif., February 8, 2012 - Geron Corporation (Nasdaq: GERN) today
announced that John A. Scarlett, M.D., President and Chief Executive Officer,
will present an overview of the company at 1:30 p.m. ET on Tuesday, February
14, 2012, at the 14th Annual BIO CEO & Investor Conference in New York City.

A live webcast of the audio and slide presentation will be available at
 www.veracast.com/webcasts/bio/ceoinvestor2012/28211446.cfm. Following the
live presentation, the webcast will be archived and available for replay at the
same address for a period of 30 days.

About Geron

Geron is a biopharmaceutical company developing first-in-class cancer
therapeutics. Imetelstat, the company's lead telomerase inhibitor, is currently
being evaluated in four Phase 2 clinical trials: metastatic breast cancer,
advanced non-small cell lung cancer, essential thrombocythemia and multiple
myeloma. GRN1005, an LRP-directed   peptide-drug conjugate, is being evaluated in
two Phase 2 clinical trials, one for brain metastases arising from breast cancer
and the other for brain metastases arising from non-small cell lung cancer. For
more information about the company, visit www.geron.com.

CONTACT:

Anna Krassowska, Ph.D.
Investor and Media Relations
650-473-7765
investor@geron.com
media@geron.com

                                      ###






This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: Geron Corp. via Thomson Reuters ONE

[HUG#1583555]